Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment

<h4>Objectives</h4> <p>To assess the efficacy and tolerability of lithium for the treatment of acute mania in children and adolescent diagnosed with bipolar disorder.</p> <h4>Methods</h4> <p>A systematic literature search up to August 2017 was conducted for...

Full description

Bibliographic Details
Main Authors: Duffy, A, Heffer, N, Goodday, S, Weir, A, Patten, S, Malhi, G, Cipriani, A
Format: Journal article
Language:English
Published: Wiley 2018
_version_ 1797054210956591104
author Duffy, A
Heffer, N
Goodday, S
Weir, A
Patten, S
Malhi, G
Cipriani, A
author_facet Duffy, A
Heffer, N
Goodday, S
Weir, A
Patten, S
Malhi, G
Cipriani, A
author_sort Duffy, A
collection OXFORD
description <h4>Objectives</h4> <p>To assess the efficacy and tolerability of lithium for the treatment of acute mania in children and adolescent diagnosed with bipolar disorder.</p> <h4>Methods</h4> <p>A systematic literature search up to August 2017 was conducted for clinical trials that included lithium in males and females up to 18 years of age with a diagnosis of bipolar disorder and experiencing a manic or mixed episode according to standardized diagnostic criteria. The protocol was registered in PROSPERO (CRD42017055675).</p> <h4>Results</h4> <p>Four independent studies described in seven manuscripts met the inclusion criteria. Overall, 176 patients were treated with lithium either as a monotherapy or adjunct to risperidone. Efficacy results suggest that lithium may be superior to placebo (standardized mean difference [SMD] −0.42, 95% confidence interval [CI] −0.88 to 0.04), comparable to sodium divalproex (SMD −0.07, 95% CI: −0.31 to 0.18), but significantly less effective than risperidone for treating protracted manic/mixed episodes and comorbid attention‐deficit hyperactivity disorder (ADHD) in prepubertal children (SMD 0.85, 95% CI: 0.54 to 1.15). Lithium was not associated with serious adverse events, and was generally well tolerated with common side effects similar to those reported in adults.</p> <h4>Conclusions</h4> <p>Limited data suggests that lithium may be an effective and tolerable treatment for some forms of paediatric mania. However, lithium is clearly inferior in efficacy to risperidone in prepubertal patients diagnosed with protracted manic/ mixed episodes and comorbid ADHD. There is a lack of data concerning the efficacy and tolerability of lithium as an acute treatment for classical mania in adolescents and important clinical issues remain unaddressed.</p>
first_indexed 2024-03-06T18:53:59Z
format Journal article
id oxford-uuid:11331fa5-2524-4fbd-8e38-d1f3330eb082
institution University of Oxford
language English
last_indexed 2024-03-06T18:53:59Z
publishDate 2018
publisher Wiley
record_format dspace
spelling oxford-uuid:11331fa5-2524-4fbd-8e38-d1f3330eb0822022-03-26T10:00:54ZEfficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatmentJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:11331fa5-2524-4fbd-8e38-d1f3330eb082EnglishSymplectic Elements at OxfordWiley2018Duffy, AHeffer, NGoodday, SWeir, APatten, SMalhi, GCipriani, A <h4>Objectives</h4> <p>To assess the efficacy and tolerability of lithium for the treatment of acute mania in children and adolescent diagnosed with bipolar disorder.</p> <h4>Methods</h4> <p>A systematic literature search up to August 2017 was conducted for clinical trials that included lithium in males and females up to 18 years of age with a diagnosis of bipolar disorder and experiencing a manic or mixed episode according to standardized diagnostic criteria. The protocol was registered in PROSPERO (CRD42017055675).</p> <h4>Results</h4> <p>Four independent studies described in seven manuscripts met the inclusion criteria. Overall, 176 patients were treated with lithium either as a monotherapy or adjunct to risperidone. Efficacy results suggest that lithium may be superior to placebo (standardized mean difference [SMD] −0.42, 95% confidence interval [CI] −0.88 to 0.04), comparable to sodium divalproex (SMD −0.07, 95% CI: −0.31 to 0.18), but significantly less effective than risperidone for treating protracted manic/mixed episodes and comorbid attention‐deficit hyperactivity disorder (ADHD) in prepubertal children (SMD 0.85, 95% CI: 0.54 to 1.15). Lithium was not associated with serious adverse events, and was generally well tolerated with common side effects similar to those reported in adults.</p> <h4>Conclusions</h4> <p>Limited data suggests that lithium may be an effective and tolerable treatment for some forms of paediatric mania. However, lithium is clearly inferior in efficacy to risperidone in prepubertal patients diagnosed with protracted manic/ mixed episodes and comorbid ADHD. There is a lack of data concerning the efficacy and tolerability of lithium as an acute treatment for classical mania in adolescents and important clinical issues remain unaddressed.</p>
spellingShingle Duffy, A
Heffer, N
Goodday, S
Weir, A
Patten, S
Malhi, G
Cipriani, A
Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment
title Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment
title_full Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment
title_fullStr Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment
title_full_unstemmed Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment
title_short Efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder: A systematic review: A report from the ISBD-IGSLi joint task force on lithium treatment
title_sort efficacy and tolerability of lithium for the treatment of acute mania in children with bipolar disorder a systematic review a report from the isbd igsli joint task force on lithium treatment
work_keys_str_mv AT duffya efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment
AT heffern efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment
AT gooddays efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment
AT weira efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment
AT pattens efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment
AT malhig efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment
AT cipriania efficacyandtolerabilityoflithiumforthetreatmentofacutemaniainchildrenwithbipolardisorderasystematicreviewareportfromtheisbdigslijointtaskforceonlithiumtreatment